http://www.biolinktherapeutics.com/

BioLink Therapeutics, Machalandapur, Kalna, West Bengal (2026)

07/04/2026

World Health Day is not just a celebration. It is a reminder of responsibility.

At BioLink Therapeutics, this day reflects the deep commitment of founders who chose the difficult path of bootstrapping, not out of convenience, but out of purpose. Without external funding, every step forward has been driven by belief in science and its power to change lives. Building from the ground up demands resilience, discipline, and an unwavering focus on impact over comfort.

Our mission is clear. To develop innovative diagnostics that enable early detection and save lives before disease progresses. To design therapies that address unmet medical needs in cancer, neurodegeneration, and antimicrobial resistance. These are not just projects. They are commitments to humanity.

Behind every idea is a scientist who refuses to give up. Behind every experiment is a vision to make medicine accessible, effective, and meaningful. World Health Day belongs to those who stay in the lab late, who continue despite setbacks, and who believe that one breakthrough can change thousands of lives.

At BioLink Therapeutics, we do not celebrate this day. We honor it by continuing the work.

www.biolinktherapeutics.com

01/04/2026

🌍 The BioLink Story: Built on Resilience and Purpose

BioLink Therapeutics did not begin with comfort. It began with uncertainty, when stability was fragile and the traditional path no longer felt secure. What followed was not just the creation of a company, but a mission shaped by resilience, grit, and belief in science-driven impact.

Bootstrapped from the ground up, BioLink was built without external funding, relying on discipline, vision, and relentless effort. As the idea evolved, it became clear that solving complex healthcare challenges required more than one approach. That vision is now restructuring into three interconnected pillars.

Global Institute for Advanced Science and Technology Inc represents the education arm, bridging academic knowledge into real-world industrial translation through hands-on training programs.
www.giastusa.org

The diagnostic division, currently in stealth mode and under registration, is focused on preventive early screening for cancer and antimicrobial resistance, aiming to shift healthcare toward early intervention.

BioLink Therapeutics continues to drive drug discovery, developing therapies in cancer, neurodegenerative diseases, antimicrobial resistance, and aging.

www.biolinktherapeutics.com

This journey is powered not by capital, but by resilience, clarity, and the courage to build without guarantees. BioLink is growing into an ecosystem where education, diagnostics, and therapeutics come together to create meaningful and scalable impact.

15/03/2026

Break the barrier. Learn, innovate, and apply your knowledge in industry-oriented projects with the Global Institute for Advanced Science and Technology (GIAST), an EdTech startup based in the United States. GIAST invites Master’s and PhD students, researchers, and professionals to enroll in the Global Internship Program on AI-Powered Computational Drug Designing, starting on 28th March. This online program offers 30 hours of structured learning across 10 modules, designed as a workshop-based, hands-on training experience that equips participants with practical skills in modern drug discovery and AI-driven computational approaches. For further details of the modules and enrollment inquiries, please contact: giastusa.org@gmail.com

28/02/2026

While transcriptomic technologies have matured, a critical gap persists in the workforce: the ability to translate RNA-level data into validated biomarkers and therapeutic targets using industry-relevant frameworks. Academic training often emphasizes methods and statistical outputs, whereas industry requires integrative interpretation—linking differential expression, pathway perturbation, target tractability, and biological relevance within a decision-driven pipeline. The Global Internship Program on Transcriptome Data Analysis addresses this gap by exposing participants to real-world datasets, translational use cases, and industry-standard analytical logic. Trainees learn not only how to analyze transcriptomic data, but how to contextualize findings within biomarker development, target prioritization, and downstream therapeutic strategy.
Send us message through the website www.biolinktherapeutics.com if you would like to join the program.
www.biolinktherapeutics.com

21/02/2026

This Global Industrial Internship Program on AI-Powered Drug Designing is built for students and professionals who want real-world, industry-driven exposure to how modern drug discovery is actually done. The program combines hands-on training with practical workflows used in biotech and pharmaceutical industries, covering AI-based target identification, structure-based drug design, molecular modeling, and data-driven decision making.

The Question/Answer sessionis designed to give prospective participants clarity on the program structure, learning outcomes, mentorship, project exposure, and career relevance, while allowing them to directly interact with the organizing team.

This session helps you understand how the internship bridges the gap between academic knowledge and industry expectations, and whether it aligns with your career goals before classes officially begin.

Message us through www.biolinktherapeutics.com

17/02/2026

BioLink Therapeutics began as a bootstrapped vision fueled by conviction rather than capital. With limited resources but expansive ambition, the founder’s team chose to work where the need was most urgent and the impact most meaningful: early cancer screening, AI-driven drug discovery, and industry-ready scientific training. Three bold missions. One lean startup.

As progress accelerated, so did responsibility. Instead of stretching one entity thin across unrelated ex*****on models, the leadership made a strategic decision that many avoid because it requires maturity: restructure before raising capital.

The vision was simple and sharp:

Each vertical deserves its own identity, governance, and growth logic.

Science moves faster when ex*****on is not diluted.

GIAST USA was formally established in the United States as a dedicated EdTech company—tasked with building a global industrial training ecosystem that converts academic knowledge into workforce-ready skill. Clear mission. Clean cap table. Scalable model.

A new diagnostic entity, now under registration, is being purpose-built to focus exclusively on biomarker-driven early cancer screening—a space where regulatory pathways, clinical validation, and partnerships demand singular attention and credibility.

And BioLink Therapeutics, returning to its scientific core, is being refined to do what it does best: build a powerful AI-enabled drug design platform and advance antimicrobial resistance research - deep tech and long-horizon science.

In conclusion, what began as multiple concepts nurtured under a single umbrella during the bootstrapping phase has now evolved with intention and clarity. Through strategic restructuring, these matured ideas have been transformed into three independent startups, each aligned to a distinct mission, market, and growth trajectory. This transition reflects disciplined leadership - recognizing when consolidation fuels survival and when separation enables scale. By giving each venture a focused direction, dedicated ex*****on strategy, and clear value proposition, the foundation has been laid for sustainable growth, stronger partnerships, and meaningful venture-scale impact.

www.biolinktherapeutics.com

14/02/2026

This global industrial internship program is designed for bachelor’s, master’s, PhD students, and working professionals who want true industry-focused, real-life, hands-on experience in AI-powered drug designing. The program goes beyond theory and classroom learning, immersing participants in practical workflows used in biotech and pharma - target identification, structure-based drug design, molecular docking, AI/ML-driven lead optimization, and data-driven decision-making. Guided by global scientists and industry mentors, participants work on real problems, real datasets, and real pipelines that reflect how modern drug discovery actually happens. Whether you are preparing for an industry career, transitioning from academia, or upskilling to stay competitive in the AI era, this internship equips you with applied skills, industry mindset, and project experience that genuinely strengthens your professional profile.

Date: 15th February 2026

⏰ Time: 8:30 AM EST
(Please mark your calendar and adjust TIME according to your local time zone.)

The Zoom meeting link is provided below for your reference.

https://us06web.zoom.us/j/83421251868?pwd=teLGalp5r0KamNkKXh0hxMcDGlRFkP.1
Meeting ID: 834 2125 1868
Passcode: 167023

05/02/2026

🌍 World Cancer Day | Early Detection Can Save Millions

Cancer remains one of India’s most urgent public health challenges - not only because of its rising incidence, but because far too many patients are diagnosed too late. In India, over 60% of cancer cases are detected at advanced stages, when treatment becomes complex, expensive, and often less effective. Early detection is the single most powerful lever to reduce cancer mortality - but current screening approaches are fragmented, urban-centric, and costly, leaving a large population underserved.

At BioLink Therapeutics, we are driven by a simple but bold mission:
👉 make early cancer detection accessible, affordable, and actionable at the point of care.

🧬 Reimagining Cancer Detection for India

Our team is developing an innovative point-of-care cancer detection technology designed specifically for real-world Indian healthcare settings from tertiary hospitals to semi-urban clinics and resource-limited environments. The goal is to enable early risk identification and screening without dependence on expensive infrastructure, long turnaround times, or centralized labs.

This approach is built to:

* Reduce diagnostic delays
* Lower overall screening costs
* Enable earlier clinical intervention
* Improve equity in cancer care access

🤝 Strategic Collaboration for Translation

To accelerate clinical translation and regulatory readiness, BioLink Therapeutics is advancing this program through a strategic collaboration with Imgenex India Pvt Ltd, a respected organization with deep expertise in translational research and diagnostic development. This partnership strengthens our pathway from laboratory innovation to real-world clinical impact.

🛡️ Regulatory Roadmap

As part of our commitment to responsible and compliant innovation, BioLink Therapeutics is targeting a CDSCO clinical trial application in late 2026, marking a critical milestone toward clinical validation and eventual deployment in India.

🌱 A Future Where Early Detection Is the Norm

On this World Cancer Day, we reaffirm our belief that early detection should not be a privilege - it should be a standard of care. By combining scientific rigor, translational partnerships, and India-centric design, BioLink Therapeutics aims to contribute meaningfully to reducing the cancer burden and improving survival outcomes across the country.

Because detecting cancer early doesn’t just save costs - it saves lives. If you are an angel investor, we would like to connect with you.
therapeuticsbiolink@gmail.com
www.biolinktherapeutics.com

19/01/2026

Antimicrobial Resistance (AMR) is one of the most urgent therapeutic challenges of our time — and incremental solutions are no longer enough.

As drug-resistant pathogens outpace traditional antibiotic pipelines, the world needs faster, smarter, and more precise therapeutic strategies. This is where AI-powered drug discovery becomes not just an advantage, but a necessity.

At BioLink Therapeutics, we are building a rare and unconventional biotech story — one that is fully bootstrapped, science-first, and platform-driven. In a world where most biotech innovation is capital-heavy from day one, BioLink belongs to a rare global category of startups advancing deep-tech biology through grit, focus, and disciplined ex*****on.

Our AMR strategy is anchored in first-of-its-kind approaches in India, beginning with two complementary therapeutic modalities:

🔹 AI-designed small molecules
Using computational intelligence to rapidly explore chemical space, evade resistance mechanisms, and accelerate lead optimization — compressing timelines that traditionally take years.

🔹 AI-engineered mini-proteins
Compact, highly specific therapeutic entities capable of targeting bacterial proteins often inaccessible to classical antibiotics. This modality remains largely unexplored in the Indian AMR ecosystem.

Beyond molecules, BioLink Therapeutics is building a proprietary, integrated AI discovery platform that unifies target biology, molecular design, resistance prediction, and translational prioritization into a single learning system.

Importantly, our preclinical discovery research — including target identification and validation — is being developed in close academic collaboration with an IIT professor, strengthening scientific rigor while remaining ex*****on-driven (A separate media release detailing this collaboration is forthcoming).

This is not just about developing drugs.
It is about building a sustainable antimicrobial innovation engine — from India, for the world.

AMR will not be solved by incremental science or isolated efforts.
It demands new modalities, computational-first thinking, and resilient biotech models.

Bootstrapped. Platform-driven. Science-led.
This is how we believe the future of AMR therapeutics must be built.

www.biolinktherapeutics.com

07/01/2026

Online Internship & Training Program
Register for the Live Q&A on AI-Powered Drug Design

BioLink Therapeutics is actively bridging academic talent with real-world industrial training through its AI-powered drug design internship and training program. We have successfully developed 30+ hours of structured course modules, combining strong theoretical foundations with hands-on exposure to computational drug discovery and AI-driven pipelines.

The response has been truly global — we are receiving overwhelming interest and queries from students across France, Egypt, Sri Lanka, Pakistan, and India, highlighting the growing demand for applied AI skills in modern biotech and pharmaceutical R&D.

🎓 Eligibility:
Students currently pursuing or holding a Bachelor’s or Master’s degree in life sciences, biotechnology, bioinformatics, pharmacy, chemistry, computer science, or related disciplines are eligible to apply. PhD students and other professionals are welcome.

🌐 Program Format:
The program is fully online, designed to be accessible globally, and offered at a minimal, affordable fees to ensure inclusivity while maintaining high-quality industrial exposure.

🚀 Register for an upcoming live Q&A and interactive sessions on 31st January, 2026 at 8:30 AM EST /7:00 PM IST where Dr. Katharine Cole, BioLink Program Director, will address student questions, career pathways, and opportunities to work on real AI-driven drug discovery projects.

Learn more about Dr. Katharine Cole, PhD.

https://www.biolinktherapeutics.com/media-release/dr-katharine-h-cole-joins-biolink-therapeutics-as-independent-director

Please register your name by messaging through the website

www.biolinktherapeutics.com

01/01/2026

Happy New Year 2026 from BioLink Therapeutics. As we step into a new year, we carry forward our commitment to innovation, scientific rigor, and purpose-driven discovery. 2026 represents new possibilities, deeper collaborations, and bold progress as we continue to design intelligent, AI-powered therapeutic solutions that can truly impact human health. We thank our collaborators, mentors, and supporters for being part of this journey, and we look forward to building the future of precision medicine together.
www.biolinktherapeutics.com

BioLink Therapeutics

07/04/2026

01/04/2026

15/03/2026

28/02/2026

21/02/2026

17/02/2026

14/02/2026

05/02/2026

19/01/2026

07/01/2026

01/01/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Share